Kamboj S K, Conroy L, Tookman A, Carroll E, Jones L, Curran H V
Clinical Psychopharmacology Unit, Research Department of Clinical, Educational and Health Psychology, University College London, UK.
Eur J Pain. 2014 Nov;18(10):1376-84. doi: 10.1002/j.1532-2149.2014.498.x. Epub 2014 Apr 3.
The effects of opioid medication on cognitive functioning in patients with cancer and non-cancer pain remain unclear.
In this mechanistic randomized, double-blind, placebo-controlled, cross-over study of patients (n = 20) receiving sustained-release and immediate-release opioid medication as part of their palliative care, we examine memory effects of an additional dose of participants' immediate-release medication (oxycodone or morphine) or placebo. Immediate prose recall and recall of related and unrelated word pairs was assessed pre-and post-drug (placebo or immediate-release opioid). Memory for these stimuli was also tested after a delay on each testing occasion. Finally, performance on an 'interference' word pair task was assessed on the two testing occasions since proactive interference has been posited as a mechanism for acute opioid-induced memory impairment.
Unlike previous work, we found no evidence of memory impairment for material presented before or after individually tailored, 'breakthrough' doses of immediate-release opioid. Furthermore, immediate-release opioid did not result in increased memory interference. On the other hand, we found enhanced performance on the interference word pair task after immediate-release opioid, possibly indicating lower levels of interference.
These results suggest that carefully titrated immediate-release doses of opioid drugs may not cause extensive memory impairment as previously reported, and in fact, may improve memory in certain circumstances. Importantly, our findings contrast strikingly with those of a study using the same robust design that showed significant memory impairment. We propose that factors, such as depressive symptoms, education level and sustained-release opioid levels may influence whether impairment is observed following immediate-release opioid treatment.
阿片类药物对癌症和非癌症疼痛患者认知功能的影响仍不明确。
在这项针对20名患者的机制性随机、双盲、安慰剂对照、交叉研究中,这些患者接受缓释和即释阿片类药物作为姑息治疗的一部分,我们研究了额外剂量的患者即释药物(羟考酮或吗啡)或安慰剂的记忆效应。在用药前和用药后(安慰剂或即释阿片类药物)评估即时散文回忆以及相关和不相关单词对的回忆。在每次测试时延迟后也对这些刺激的记忆进行测试。最后,在两个测试场合评估“干扰”单词对任务的表现,因为前摄干扰被认为是急性阿片类药物引起记忆损害的一种机制。
与之前的研究不同,我们没有发现证据表明在个体化定制的“突破性”即释阿片类药物剂量前后呈现的材料存在记忆损害。此外,即释阿片类药物并未导致记忆干扰增加。另一方面,我们发现即释阿片类药物后干扰单词对任务的表现有所提高,这可能表明干扰水平较低。
这些结果表明,仔细滴定的即释阿片类药物剂量可能不会像之前报道的那样导致广泛的记忆损害,事实上,在某些情况下可能会改善记忆。重要的是,我们的研究结果与一项采用相同稳健设计但显示出显著记忆损害的研究结果形成了鲜明对比。我们提出,诸如抑郁症状、教育水平和缓释阿片类药物水平等因素可能会影响即释阿片类药物治疗后是否会观察到损害。